Cancers · Nov 15, 2026
GLP-1-Based Therapies in Endometrial Cancer: Metabolic Effects, Fertility-Sparing Strategies, and Emerging Clinical Evidence
By Yordanov A, Yanachkova V, Tsoneva E et al.
Background/Objectives: GLP-1-based therapies have attracted interest in endometrial cancer because obesity and metabolic dysfunction are common and biologically relevant to the disease. This review examines their metabolic, experimental, and emerging clinical roles, particularly during fertility-sparing treatment. Methods: This focused narrative synthesis integrates relevant preclinical, translational, and clinical studies, interpreted qualitatively according to design, comparator, endpoint relevance, and translational limitations. Results: Weight reduction and improved metabolic health provide a rationale for investigation. Experimental studies suggest effects on proliferation, apoptosis, and progesterone responsiveness, but results vary across models. Observational cancer-incidence associations depend on comparator choice and do not establish prevention. Early fertility-sparing cohorts report clinical signals, including lower hysterectomy rates, but do not establish a drug-specific pathological or reproductive benefit independent of weight loss and concurrent progestin treatment. No molecular subgroup or hormone receptor profile has been validated as a predictor of benefit. Preconception discontinuation and subsequent weight regain require explicit evaluation. There is no established antineoplastic role in advanced or recurrent disease. Conclusions: GLP-1-based therapies have established metabolic applications, whereas their oncologic benefit in endometrial cancer remains unproven. Controlled studies incorporating pathological, metabolic, molecular, and reproductive outcomes are needed before cancer-specific use can become standard care.